Market Overview

RXi Pharmaceuticals Announces Phase 1 Study Results for RXI-109


RXi Pharmaceuticals Corporation (OTC: RXII) today announced the pharmacokinetic results of their
single dose Phase 1 study with RXI-109 in healthy subjects. This drug
candidate is a highly selective CTGF targeting sd-rxRNA® compound that
is administered through intradermal injections to prevent or
reduce dermal scarring following surgery or trauma, as well as for the
management of hypertrophic scars and keloids.

In this study, 15 volunteers divided over 5 cohorts received single
intradermal injections in a dose escalating manner, and blood was drawn
at various time points to evaluate the distribution of the drug beyond

See full press release

Posted-In: News Guidance


Related Articles (RXII)

View Comments and Join the Discussion!

Partner Center